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Abstract
Aim To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused
by antiandrogen therapy for prostate cancer.
Methods The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published
and assessed the validity of the information on efficacy and treatment-related toxicity.
Results Eight randomized controlled trials and one meta-analysis were identified. Two randomized trials demonstrated
that prophylactic radiation therapy (RT) using 1× 10Gy or 2× 6Gy significantly reduced the rate of gynecomastia but not
breast pain, as compared to observation. A randomized dose-finding trial identified the daily dose of 20mg tamoxifen
(TMX) as the most effective prophylactic dose and another randomized trial described that daily TMX use was superior to
weekly use. Another randomized trial showed that prophylactic daily TMX is more effective than TMX given at the onset
of gynecomastia. Two other randomized trials described that TMX was clearly superior to anastrozole in reducing the risk
for gynecomastia and/or breast pain. One comparative randomized trial between prophylactic RT using 1× 12Gy and TMX
concluded that prophylactic TMX is more effective compared to prophylactic RT and furthermore that TMX appears to be
more effective to treat gynecomastia and/or breast pain when symptoms are already present. A meta-analysis confirmed that
both prophylactic RT and TMX can reduce the risk of gynecomastia and/or breast pain with TMX being more effective;
however, the rate of side effects after TMX including dizziness and hot flushes might be higher than after RT and must
be taken into account. Less is known regarding the comparative effectiveness of different radiation fractionation schedules
and more modern RT techniques.
 Pirus Ghadjar, MD
Pirus.ghadjar@charite.de
1 Department of Radiation Oncology, Charité –
Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Berlin, Germany, Augustenburger
Platz 1, 13353 Berlin, Germany
2 Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland
3 Klinikum Nürnberg Nord, Nürnberg, Germany
4 Universitätsklinikum Würzburg, Würzburg, Germany
5 Innsbruck Medical University, Innsbruck, Austria
6 Xcare Praxis für Strahlentherapie Saarlouis, Xcare Gruppe,
Saarlouis, Germany
7 Universitätsklinikum Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany
8 Universitätsklinikum Tübingen, Tübingen, Germany
9 Sana Klinikum Offenbach, Offenbach, Germany
10 MediClin Robert Janker Klinik, Bonn, Germany
11 Landeskrankenhaus, Universitätsklinikum der Paracelsus
Medizinischen Privatuniversität, Salzburg, Austria
12 Universitätsklinikum Ulm, Ulm, Germany
K
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
24
35
 
| 
do
wn
lo
ad
ed
: 
13
.5
.2
02
0
Strahlenther Onkol
Conclusions Prophylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast
pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but
its side effects and off-label use must be considered.
Keywords Gynecomastia · Breast pain · Prostate cancer · Antiandrogen therapy · Treatment
Introduction
Androgen deprivation therapy (ADT) is commonly used in
metastatic prostate cancer (PCA) or combined with primary
radiation therapy (RT) for patients with localized PCA with
intermediate- to high-risk features, locally advanced PCA
or biochemically recurrent prostate cancer [1–3].
A common side effect of ADT, due to the disturbed
balance between estrogens and androgens throughout the
body, can be swelling of the male breast called gynecomas-
tia and/or breast pain (mastodynia). Generally, stimulation
of estrogen receptors in the breast tissue stimulate growth,
while stimulation of androgen receptors inhibits growth.
Nonsteroidal antiandrogens like bicalutamide or flutamide
block androgen receptors, which through a feedback loop
increase the secretion of luteinizing hormone (LH). In-
creased LH stimulates testosterone secretion, which, how-
ever, is then converted to estrogen by peripheral aromatiza-
tion [4]. As androgen receptors are blocked by nonsteroidal
antiandrogens, the increased level of estrogen stimulating
the estrogen receptor in breast tissue stimulates growth,
leading to gynecomastia and/or breast pain [4].
Gynecomastia and/or breast pain can be observed in up
to 85% of patients after therapy with high-dose nonsteroidal
antiandrogens, negatively impacting patients’ quality of live
(QoL) and treatment compliance [1].
The use of enzalutamide, an androgen receptor signal-
ing inhibitor, besides binding to the androgen receptor in-
hibiting also DNA binding and coactivator recruitment, has
likewise been shown to be associated with a 49% rate of
gynecomastia and 21% rate of nipple pain within 2 years
[5]. A lower rate of gynecomastia and/or breast pain of
only around 13–22% is observed, when combined andro-
gen blockade is used [1].
For apalutamide, a new selective androgen signal in-
hibitor, gynecomastia is not described as a drug-related side
effect.
ADT-related gynecomastia and/or breast pain can be
treated by antiproliferative low-dose RT to the breasts. Al-
ternatively, gynecomastia and/or breast pain can be treated
by drug intervention using either tamoxifen (TMX) which
blocks the estrogen receptor, or theoretically by anastro-
zole which inhibits the peripheral aromatization of andro-
gens into estrogens. Surgery might also be a treatment op-
tion but due to its invasiveness is commonly preserved for
those patients were aforementioned treatments have failed
[1, 4]. The literature supporting the use of these treatment
approaches is reviewed in the following.
Materials andmethods
Complete reports of randomized controlled trials or meta-
analysis of RCTs of RT and/or drug interventions to prevent
gynecomastia and/or breast pain (prophylactic treatment) or
to treat existing gynecomastia and/or breast pain (therapeu-
tic treatment) in patients receiving ADT for prostate can-
cer were searched in May 2019 using MEDLINE, Current
Contents, PubMed, and references from relevant articles.
The search strategy included the terms “prostate cancer”,
“androgen deprivation therapy”, “hormonal therapy”, “an-
tiandrogen therapy”, “gynecomastia”, “breast pain”, “mas-
todynia”, “treatment”, alone or in combination.
The primary objective was efficacy to treat gynecomastia
and/or breast pain as well as treatment-related toxicities.
Original articles written in English language and pub-
lished in peer-reviewed journals after the year 2000 were
included. Two authors (P.G. and T.W.) selected studies for
inclusion.
Results
Characteristics of included studies
A total of 8 randomized controlled trials (one trial with
two randomizations) and one meta-analysis was identified
testing the effect of radiation therapy for ADT-related gy-
necomastia and/or breast pain. Two randomized controlled
trials compared prophylactic RT with no RT or sham RT [6,
7]. Two randomized controlled trials compared prophylactic
TMX with different dosage and application schedule [8, 9].
Two trials compared TMX vs. anastrozole or placebo [10,
11]. One trial compared prophylactic TMX vs. therapeutic
TMX [12]. One trial compared no prophylaxis, prophylac-
tic RT with prophylactic TMX [13, 14]. Patients from the
control arm of the latter trial, who subsequently developed
gynecomastia, were randomized to therapeutic RT vs. ther-
apeutic TMX [13, 14].
A meta-analysis included five randomized controlled tri-
als analyzing RT vs. observation or RT vs. TMX, or TMX
vs. observation [15].
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Table 1 Characteristics of prospective randomized controlled trials evaluating the role of radiation therapy for ADT-related gynecomastia and/or
breast pain
Publication/
author
Patients
(N)
Trial design Study
period
Interventions and results Side effects and/or QoL
Tyrell et al.
[6]
106 Randomized,
sham con-
trolled,
double blind
11/1999–
06/2001
Prophylactic single dose electron beam RT with 10Gy
vs. sham RT.
RT reduced gynecomastia 52% vs. 85%; OR, 0.13;
95% CI, 0.04–0.38; p< 0.001. Breast pain was sim-
ilar in both arms (83% vs. 91%; OR, 0.25; 95% CI,
0.05–1.27; p= 0.221) but severity of pain tended to
improve after RT (p= 0.043)
RT-related adverse events
were experienced by 17
of 52 patients (33%) who
received RT (breast/nipple
erythema, breast/nipple
tenderness, or skin irritation)
Ozen et al.
[7]
125 Randomized 06/2003–
10/2005
Prophylactic RT using 2× 6Gy electron beam vs. no
RT
RT reduced gynecomastia 15.8% vs. 50.8% while the
rate of breast pain was similar being 36.4% vs. 49.2%
Adverse events were mild
and observed in 6 or 8 pa-
tients per treatment arm
ADT androgen deprivation therapy, QoL quality of life, RT radiation therapy, OR odds ratio, CI confidence interval, n.a. not available
No randomized trials were found using surgery as treat-
ment modality for gynecomastia and/or breast pain.
Radiation therapy
The two identified randomized controlled trials are summa-
rized in Table 1 testing the effect of radiation therapy for
ADT-related gynecomastia and/or breast pain.
One randomized trial was conducted in a double blind,
sham-controlled fashion. One hundred-six prostate cancer
patients who underwent bicalutamide treatment were ran-
domized to prophylactic single dose electron beam RT with
10Gy vs. sham RT [6]. The dose was directed to a 5-cm
diameter circle of tissue centered around each nipple and
a minimum dose of 90% was required between the skin and
the chest wall using 6–12MeV. RT reduced gynecomastia
to rates of 52% vs. 85% (odds ratio [OR], 0.13; 95%, con-
fidence interval [CI], 0.04–0.38; p< 0.001) after one year.
Breast pain was similar in both arms (83% vs. 91%; OR,
0.25; 95% CI, 0.05–1.27; p= 0.221) but developing pain
appeared to be less severe after RT (p= 0.043) [6].
In another randomized controlled trial in 125 prostate
cancer patients who underwent bicalutamide treatment the
use of prophylactic electron beam RT using 2× 6Gy vs.
observation significantly reduced the rate of gynecomastia
from 50.8% to 15.8% (p< 0.001) after one year, while the
incidence of breast pain was not significantly lower (36.4%
vs. 49.2%, respectively). RT was directed toward a 5cm
diameter circle of tissue centered on each nipple. The dose
was prescribed to the 90% isodose line covering the su-
perficial 3–4mm of the pectoral muscle using 6 to 12MeV
[7].
Drug therapy
The five identified randomized controlled trials testing the
effect of drug therapy for ADT-related gynecomastia and/or
breast pain are summarized in Table 2.
In a placebo-controlled randomized dose–response
study, TMX was tested as prophylactic treatment in 282
prostate cancer patients undergoing bicalutamide therapy
[8].
Patients were randomized to different doses of TMX (1,
2.5, 5, 10, or 20mg/day) or placebo given for 12 months
during bicalutamide therapy, followed by 12 months where
bicalutamide was given alone. Primary endpoint was
breast-related events (gynecomastia and/or breast pain)
at 6 months. Increasing doses of TMX were associated
with a decreased incidence of breast events in a dose-
dependent manner at the 3-, 6- and 12-month assessments.
At 6 and 12 months breast events were presented in 96.7%
or 98.3% of patients after placebo and in 8.8% or 20.6%
of patients after 20mg TMX. At 24 months (i.e., after
12 months of bicalutamide monotherapy), a high incidence
of breast events (>90%) was seen in all groups. There was
no evidence of a negative effect of TMX on PSA inhibi-
tion at any assessment compared to placebo. An increased
incidence of dizziness and hot flushes was observed with
prophylactic TMX [8].
In another trial in which prostate cancer patients under-
went bicalutamide treatment patients were randomized into
either 20mg daily TMX continuously or 20mg daily TMX
for the first 8 weeks, then at a single weekly dose of 20mg
thereafter for a total of 36 months (or for 24 months in
selected patients) in both arms. The trial was stopped early
after inclusion of 80 evaluable patients after a planned in-
terims analysis showed the inferiority of the weekly TMX
schedule. Breast ultrasonography was used as an objective
technique to monitor gynecomastia. There was no differ-
ence in treatment-related toxicity between the trial arms.
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Table 2 Characteristics of prospective randomized controlled trials evaluating the role of drug therapy for ADT-related gynecomastia and/or
breast pain
Publication/
author
Patients
(N)
Trial design Study
period
Interventions and results Side effects and/or
QoL
Fradet
et al. [8]
282 Randomized,
placebo
controlled
11/2002–
06/2003
Patients were randomized to different prophylactic doses
of TMX (1, 2.5, 5, 10, or 20mg/day) or placebo given
for 12 months. Increasing doses of TMX decreased inci-
dence of breast events (gynecomastia and/or breast pain)
in a dose-dependent manner at the 3-, 6- and 12-month as-
sessments, where breast events were presented in 96.7% or
98.3% after placebo and in 8.8% or 20.6% of patients after
20mg TMX. At 24 months (i.e., after 12 months of bica-
lutamide monotherapy), a high incidence of breast events
(>90%) was seen in all groups
Dizziness and hot
flushes increased
by TMX
Bedognetti
et al. [9]
80 Randomized,
noninferior-
ity
12/2003–
2/2006
Patients were randomized to prophylactic daily TMX 20mg
or daily TMX 20mg for 8 weeks and weekly TMX 20mg
thereafter. After a preplanned interims analysis gynecomas-
tia developed in 31.7% of patients in the daily group and in
74.4% of patients in the weekly group (p< 0.0001), and it
was more severe in patients who switched to weekly tamox-
ifen (p= 0.001). Mastalgia occurred in 12.2 and 46.1% of
patients, respectively (p= 0.001)
No difference in
treatment-related
toxicity
Saltzstein
[10]
107 Randomized,
placebo
controlled
n.a. Patients were randomized to 3 months of prophylactic daily
TMX 20mg or daily anastrozole 1mg or placebo. After
3 months bicalutamide was continued for another 9 months.
Patients who developed gynecomastia and/or breast pain
during this period underwent TMX or anastrozole for
3 months. The incidence of gynecomastia and/or breast
pain was 11.8% for TMX, 63.9% for anastrozole and 69.4%
for placebo (p< 0.0001). Resolution of gynecomastia and
breast pain for therapeutically treated patients occurred in
65.4% in the TMX group, 71.8% of patients in the placebo
group (who received TMX) and 18.8% of patients in the
anastrozole group
Dizziness in-
creased by TMX
Boccardo
[11]
114 Randomized,
placebo
controlled
12/2000–
12/2002
Patients were randomized to 48 weeks of prophylactic daily
TMX 20mg or daily anastrozole 1mg or placebo. Gyneco-
mastia developed in 73% of patients in the bicalutamide
group, 10% of patients in the bicalutamide-TMX group,
and 51% of patients in the bicalutamide-anastrozole group
(p= 0.001); breast pain developed in 39%, 6% and 27% of
patients, respectively (p= 0.006)
Treatment was
well tolerated and
the incidence of
toxicity was higher
in the anastrozole
arm (69.5% of pa-
tients) as compared
to placebo (37.5%)
or TMX (35.1%)
Serretta
[12]
176 Randomized
controlled
06/2005–
06/2007
Patients were randomized to 1 year daily 20mg TMX
within 1 month from the onset of gynecomastia and/or
breast pain (Arm A, therapeutic treatment) or 1 year pro-
phylactic daily 10mg TMX (Arm B). In Arm A gyneco-
mastia and/or breast pain increased with time with a rate of
39.8%, 57.8%, 69.9% and 78.3% at 3, 6, 9, and 12 months
after initiation of bicalutamide. After therapy with TMX gy-
necomastia and/or breast pain persisted in 27.7% of cases.
In arm B, the prevalence of gynecomastia and/or breast
pain was 35% after 12 months of therapy. The difference
in gynecomastia and/or breast pain between the 2 arms
was statistically significant (p= 0.0001). The differences
in prevalence of gynecomastia and breast pain between
the 2 arms both favored TMX prophylaxis (p= 0.0001 and
p= 0.001, respectively)
No significant
difference between
the trial arms
ADT androgen deprivation therapy, TMX Tamoxifen, QoL quality of life
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Again, no negative effect on PSA inhibition was observed
[9].
Saltzstein et al. included 107 patients with prostate can-
cer who received bicalutamide therapy in a randomized
placebo-controlled trial comparing 3 months of prophylac-
tic daily 20mg TMX with daily 1mg anastrozole or placebo
with the primary endpoint being gynecomastia and/or breast
pain after 3 months. After the 3-month prophylactic treat-
ment patients continued for another 9 months with the bica-
lutamide treatment [10]. When gynecomastia and/or breast
pain was observed during this period, TMX or anastro-
zole where given again for 3 months or for patients of the
placebo group 20mg of daily TMX was applied. The in-
cidence of gynecomastia and/or breast pain was 11.8% for
TMX, 63.9% for anastrozole and 69.4% for placebo, re-
spectively (p< 0.0001). Interpretation of the results at 6,
9, and 12 months after randomization was confounded by
the retreatment of some patients with TMX or anastro-
zole for gynecomastia/breast pain developing before these
timepoints, and therefore not presented. The number of pa-
tients actively retreated for gynecomastia/breast pain in the
TMX, anastrozole, and placebo groups was 26 (76.5%),
32 (88.8%), and 32 (88.8%), respectively. Resolution of
gynecomastia and breast pain occurred in 65.4% of pa-
tients in the TMX group, 71.8% of patients in the placebo
group (who received TMX) and 18.8% of patients in the
anastrozole group [10]. The incidence of treatment-related
dizziness appeared to be higher in the TMZ arm of the
trial. Although serum testosterone levels in the TMX group
were higher than those in the placebo group during the pro-
phylactic phase of the clinical trial, any adverse impact of
combination therapy on cancer control as assessed by PSA
levels could not be observed during the trial [10].
In a placebo-controlled randomized trial on prostate can-
cer patients who received bicalutamide therapy, 114 pa-
tients were randomized into 48 weeks of prophylactic daily
20mg TMX, or daily 1mg anastrozole or placebo. Gyneco-
mastia developed in 73% of patients in the bicalutamide
group, 10% of patients in the bicalutamide–TMX group,
and 51% of patients in the bicalutamide–anastrozole group
(p= 0.001); breast pain developed in 39%, 6%, and 27% of
patients, respectively (p= 0.006). Treatment was well toler-
ated and the incidence of toxicity was higher in the anas-
trozole arm (69.5% of patients) as compared to placebo
(37.5%) or TMX (35.1%). There was no major difference
among groups regarding PSA response [11].
Serretta et al. conducted a randomized controlled trial on
176 patients with prostate cancer undergoing bicalutamide
therapy. Patients were randomized to either 1 year daily
20mg TMX within 1 month from the onset of gynecomas-
tia and/or breast pain (Arm A, therapeutic treatment) or
1 year prophylactic daily 10mg TMX (Arm B). In Arm A
gynecomastia and/or breast pain increased with time with
a rate of 39.8%, 57.8%, 69.9%, and 78.3% at 3, 6, 9, and
12 months after initiation of bicalutamide. After therapy
with TMX gynecomastia and/or breast pain persisted in
27.7% of cases. In arm B, the prevalence of gynecomastia
and/or breast pain was 35% after 12 months of therapy. Al-
though TMX was quite effective in the majority of patients
of arm B, the action of the drug was slow, with only 18.5%
of patients having a clinical response after 3 months of ther-
apy. After 6 months of TMX therapy, the response rate was
43.8%, and many other patients required up to 12 months
of administration. The difference in gynecomastia and/or
breast pain between the two arms was statistically signifi-
cant (p= 0.0001). The differences in prevalence of gyneco-
mastia and breast pain between the two arms both favored
TMX prophylaxis (p= 0.0001 and p= 0.001, respectively).
There was no difference in toxicity observed between the
trial arms and there was no difference in PSA control be-
tween the trial arms [12].
Radiation therapy vs. drug therapy
Table 3 summarized the identified randomized controlled
trial comparing radiation therapy and drug therapy with
two randomizations for ADT-related gynecomastia and/or
breast pain.
A randomized controlled trial on 102 prostate cancer
patients who underwent bicalutamide treatment random-
ized patients in a control arm or to receive prophylactic
daily 10mg TMX over 24 weeks or prophylactic RT using
1× 12Gy. RT was administered as an electron beam di-
rected to irradiate a 5cm diameter circle of tissue centered
around each nipple and was designed to deliver a minimum
dose of 90% between the skin and the chest wall. An appro-
priate electron energy of 6–12MeV was selected to cover
the depth of tissue.
Patients from the control arm who developed gyneco-
mastia and/or breast pain were subsequently randomized to
TMX or RT [13].
Of the control group 67% of patients developed gyneco-
mastia compared with 8% after prophylactic TMX and 34%
after prophylactic RT. Regarding the power of the study,
prophylactic TMX and prophylactic RT both reduced ex-
pected frequency by 50% or more and were therefore effec-
tive. However, breast pain was more frequent in the con-
trol group than after TMX or RT (58% vs 7% and 30%,
respectively). Differences were significant (p= 0.001 and
p= 0.01). In patients of the control group who had gyneco-
mastia and/or breast pain a significant decrease in symp-
toms was achieved in those receiving TMX (p= 0.05). There
was no difference of treatment-related toxicity or PSA con-
trol between the two arms [13].
Data from the latter trial were published again but with
more included patients and with similar main results [14].
K
Strahlenther Onkol
Table 3 Characteristics of prospective randomized controlled trials comparing radiation therapy and tamoxifen for ADT-related gynecomastia
and/or breast pain
Publication/
author
Patients
(N)
Trial de-
sign
Study
period
Interventions and results Side effects and/or
QoL
Di Lorenzo
et al. [13]
102 Randomized
controlled
01/2002–
02/2004
Patients were randomized no additional treatment (control
arm) or prophylactic daily 10mg TMX over 24 weeks or
prophylactic low dose RT using 1× 12Gy. Patients from the
control arm who developed gynecomastia and/or breast pain
were subsequently randomized to TMX or RT.
Of the control group 67% of patients developed gyneco-
mastia compared with 8% after prophylactic TMX and 34%
after prophylactic RT. Breast pain was more frequent in the
control group than after TMX or RT (58% vs 7% and 30%,
respectively). Differences were significant (p= 0.001 or
p= 0.01). In patients of the control group who had gyneco-
mastia and/or breast pain a significant decrease in symptoms
was achieved in those receiving TMX (p= 0.05)
For further information compare below (Perdonà et al.)
There were no sig-
nificant differences
between the groups
with respect to toxic-
ity
Perdonà
et al. [14]
151 Randomized
controlled
01/2002–
02/2004
Same trial as Di Lorenzo et al., published with a larger num-
ber of patients but basically the same results
There were no sig-
nificant differences
between the groups
with respect to toxic-
ity
ADT androgen deprivation therapy, QoL quality of life, RT radiation therapy
The 35 patients allocated in the control arm (initial random-
ization) who developed gynecomastia and/or breast pain
were subsequently randomly assigned to TMX (n= 17) or
RT (n= 18). In this subgroup, TMX significantly reduced
the frequency of gynecomastia (p= 0.02). After 6 months
and 9 months, gynecomastia was recorded in 2 of 17 pa-
tients allocated TMX compared with 10 of 18 allocated
RT. Of these 35 patients, 29 developed concomitant gy-
necomastia and breast pain, and a higher reduction in pain
was recorded in the TMX group than in the RT group
(p= 0.045). After 6 months and 9 months, breast pain was
reported in 4 of 14 patients assigned TMX compared with
12 of 15 assigned RT.
A recent meta-analysis included five randomized trials
[6–8, 11, 14] with a total of 777 patients to explore the
effects of prophylactic low-dose RT or TMX for patients
who underwent ADT for prostate cancer [15]. Pooled re-
sults from the trials comparing RT vs. observation showed
a significant reduction in the incidence of gynecomastia
and breast pain rates in patients treated with RT (OR, 0.21;
95% confidence interval [CI], 0.12–0.37, p< 0.0001, and
OR, 0.34; 95% CI 0.20–0.57, p< 0.0001, respectively). Use
of RT resulted in an absolute risk reduction of 29.4 and
19.9%, with a number needed to treat of 3.4 and 5 to
avoid one case of gynecomastia and breast pain, respec-
tively. In comparison, pooled results from trials comparing
TMX vs. observation likewise showed a statistical benefit
for breast pain and gynecomastia in favor of TMX arms
(OR, 0.04; 95% CI, 0.02–0.08, p< 0.0001 and OR, 0.07;
95% CI, 0.0–0.14, p< 0.00001). TMX resulted in a larger
absolute risk reduction of 64.1% and 47.6%, with a num-
ber needed to treat to avoid one case of gynecomastia and
breast pain of 1.56 and 2.1, respectively.
Considering adverse effects, these were reported in three
included trials with a total population of 330 patients within
the meta-analysis. The incidence of adverse effects (ery-
thema, pruritus or hyperpigmentation) were highest in the
RT arms (45/155; 29%) compared with observation arms
(48/175; 27.4%), resulting in an absolute risk increase to
harm of 1.6% and number needed to harm of 62.5. On the
other hand, the incidence of adverse effects in TMX arms
was higher (mostly dizziness and hot flushes) compared
to the observation arms (47/121; 38.8% vs. 44/151; 29%)
with an absolute risk increase to harm of 9.8% and a number
needed to harm of 10 [13]. The authors concluded that TMX
was two times more effective in preventing gynecomastia;
however, low-dose RT represents an effective and safe treat-
ment option, to take into account mainly in patients with
cardiovascular risk factors or thrombotic diathesis [15].
Discussion
The incidence of gynecomastia and/or breast pain after
treatment with nonsteroidal antiandrogens or more recently
also with enzalutamide is high and effective prophylactic
and therapeutic treatments are important. Prophylactic RT
(1× 10–12Gy or 2× 6Gy) is generally well tolerated and
can significantly reduce gynecomastia and to a lesser ex-
tent breast pain. Secondary cancers are generally a risk af-
ter every RT; however, the risk after usage of lower-doses,
usually used for treatment of benign diseases, renders the
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development of second cancers, to the best of our knowl-
edge, very unlikely [16]. Likewise, in a registry-based study
on prophylactic RT of the breast in prostate cancer patients,
the risk of second cancers was not increased [17].
Daily 20mg TMX is also a well-established approach
and appears to be more effective than RT for prophylaxis
and therapeutic treatment for gynecomastia and/or breast
pain [13–15]. TMX, however is associated with a well-
documented rate of side effects, mostly dizziness [8, 10]
and hot flushes [8], whereby the latter might be additive
to those produced by ADT, which would adversely affect
tolerability of ADT. In addition, the risk of thromboem-
bolic events is significantly increased in older (≥71 years)
male patients who undergo TMX treatment for breast can-
cer [18]. Regarding the risk of secondary cancers due to
TMX treatment, in females an increase of endometrial can-
cers is well-documented, long-term data for prostate cancer
patients receiving TMX is not available to estimate the risk
of secondary cancers in men. There was no evidence in any
of the randomized controlled trials that there is a negative
effect of TMX on PSA control, at any assessment compared
to placebo [8–12].
The resolution rate for gynecomastia is strictly related to
the duration of therapy with bicalutamide [14]. Resolution
of gynecomastia and breast pain occurred in round about
two thirds of patients who were therapeutically retreated
with 3 months of 20mg daily TMX, or in patients with
manifest gynecomastia and/or breast pain who were treated
with 3 months of 20mg daily TMX for the first time [10].
As expected, based on the pharmacologic mechanisms
involved, the benefits of prophylactic TMX 20mg do not
persist once therapy was discontinued [10]. Therefore, it is
probably required to remain on TMX throughout the course
of ADT treatment to maintain a prophylactic effect [8].
Notably, the use of TMX in prostate cancer patients is an
off-label use and liability issues may apply for prescribing
doctors.
Although low-dose breast RT is usually well tolerated
and allows patients to avoid year-long exposition to TMX,
late cardiac effects and secondary malignant disease might
be of some concern following the delivery of this treatment,
especially in the individuals with longer life expectancies,
like those who are candidates to receive bicalutamide as
an adjuvant treatment [19]. This can however be reduced to
a minimum when the appropriate electron energy is chosen.
A comparative histologic examination of breast tissue
one year after RT with 12.5Gy (3 fractions) and normal
tissue without previous RT found a significantly improved
but not completely inhibited diethylstilboestrol-induced gy-
necomastia [20]. Gynecomastia can be characterized into
two distinct subtypes (type I, increased number of ducts
and marked proliferation of ductal epithelia; and type II,
minimal proliferation but changes to the stroma and struc-
tural components of the breast) [21], it is possible that RT
only prevents the proliferative change (type I). Thus, more
studies using different schedules of fractionation achiev-
ing higher biological doses with conformal RT techniques
should be performed to further reduce the incidence of gy-
necomastia and/or breast pain without increasing the risk
of toxicity associated with RT [15, 22].
For clinical practice, besides the comparative effective-
ness of TMX and RT also side effects have to be considered.
Although RT appears to be less effective than TMX as pro-
phylactic treatment, side effects of RT are only modest and
of short duration, whereas the side effects of TMX are usu-
ally lasting throughout the whole course of therapy. Patients
need to be counseled well regarding this and it might also
be an option to start prophylactic RT and switch to TMX,
when RT should turn out to be not effective enough.
Due to the associated high incidence of gynecomastia
and/or breast pain, prophylactic treatment should only be
offered to patients undergoing treatment with nonsteroidal
antiandrogens or enzalutamide but not to patients under-
going treatment with other forms of ADT. Currently, gy-
necomastia is not an issue with the new antiandrogen apa-
lutamide.
Unfortunately, there is no evidence from randomized tri-
als available regarding different fractionation schedules of
RT neither as a prophylactic or therapeutic treatment. To-
day, besides the established 1× 10–12Gy single shot treat-
ment, or the 2× 6Gy schedule, commonly hypofractionated
schedules with 3–5 fractions of 3Gy are applied, as re-
cently reviewed by the guideline for radiotherapy of benign
diseases published by the German Society for Radiation
Oncology (DEGRO) and others [23, 24].
For therapeutic treatment of existing gynecomastia
and/or breast pain again, TMX is more effective than
RT; however, treatment-associated side effects and their
duration also have to be considered in decision making and
discussed with patients.
For therapeutic RT of existing gynecomastia and/or
breast pain even higher doses of around 30–40Gy total
dose are used and recommended [23], but there is no data
available supporting this strategy and more data is needed
to confirm that this higher dose approach is associated with
increased effectivity.
Anastrozole has been shown to be ineffective for the
prophylactic treatment of gynecomastia and/or breast pain
and should therefore not be used [10, 11].
Long-standing gynecomastia resulting from the fibrotic
changes in the adipose tissue appears to be best managed
by surgery [25]. However, breast surgery can be associ-
ated with complications such as doughnut deformity, nipple
necrosis, nipple flatting, and loss of sensation [26].
K
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Conclusions
Prophylactic RT as well as daily TMX can significantly
reduce the incidence of gynecomastia and/or breast pain.
TMX appears to be an effective alternative to RT also as
a therapeutic treatment in the presence of gynecomastia but
its side effects and off-label use must be considered.
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